BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
0.2972
+0.0012 (0.41%)
At close: Mar 27, 2026, 4:00 PM EDT
0.3210
+0.0238 (8.01%)
After-hours: Mar 27, 2026, 7:57 PM EDT

BioRestorative Therapies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.360.40.150.120.05
Revenue Growth (YoY)
-10.30%175.03%21.70%160.44%-40.26%
Cost of Revenue
0.020.03---
Gross Profit
0.340.370.15--
Selling, General & Admin
5.895.2211.3315.5825.62
Research & Development
10.096.714.033.510.73
Total Operating Expenses
15.9811.9315.3719.0926.35
Operating Income
-15.98-11.93-15.37-19.09-26.35
Interest Income
0.270.620.55-0.01-
Interest Expense
----1.82
Other Non-Operating Income (Expense)
2.544.549.05-11.4934.18
Total Non-Operating Income (Expense)
2.815.159.61-11.535.99
Pretax Income
-13.17-6.78-5.76-30.69.64
Net Income
-14.24-8.98-10.42-13.22-44.3
Net Income to Common
-14.24-8.98-10.42-13.22-44.3
Shares Outstanding (Basic)
98441
Shares Outstanding (Diluted)
98441
Shares Change (YoY)
15.83%84.05%16.60%204.60%200.92%
EPS (Basic)
-1.58-1.16-2.47-3.65-37.30
EPS (Diluted)
-1.58-1.16-2.47-3.65-37.30
Free Cash Flow
-10.91-8.34-6.6-6.18-3.36
Free Cash Flow Per Share
-1.21-1.07-1.56-1.71-2.83
Gross Margin
93.37%93.00%100.00%100.00%100.00%
Operating Margin
-4443.42%-2974.59%-10539.49%-15938.08%-57291.03%
Profit Margin
-3662.13%-1689.90%-3950.91%-25540.30%20949.94%
FCF Margin
-3031.70%-2078.94%-4527.61%-5157.20%-7305.58%
EBITDA
-15.77-11.74-15.2-18.97-26.26
EBITDA Margin
-4385.04%-2927.45%-10425.82%-15837.46%-57097.32%
EBIT
-15.98-11.93-15.37-19.09-26.35
EBIT Margin
-4443.42%-2974.59%-10539.49%-15938.08%-57291.03%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q